These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36632339)

  • 1. Adjunctive minocycline for major depressive disorder: A sub-study exploring peripheral immune-inflammatory markers and associated treatment response.
    Walker AJ; Mohebbi M; Maes M; Berk M; Walder K; Bortolasci CC; Liu ZS; Ng CH; Ashton MM; Berk L; Singh AB; Malhi GS; Dean OM
    Brain Behav Immun Health; 2023 Feb; 27():100581. PubMed ID: 36632339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minocycline as adjunctive treatment for major depressive disorder: Pooled data from two randomized controlled trials.
    Zazula R; Husain MI; Mohebbi M; Walker AJ; Chaudhry IB; Khoso AB; Ashton MM; Agustini B; Husain N; Deakin J; Young AH; Berk M; Kanchanatawan B; Ng CH; Maes M; Berk L; Singh AB; Malhi GS; Dean OM
    Aust N Z J Psychiatry; 2021 Aug; 55(8):784-798. PubMed ID: 33092404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring interleukin-6, lipopolysaccharide-binding protein and brain-derived neurotrophic factor following 12 weeks of adjunctive minocycline treatment for depression.
    Hasebe K; Mohebbi M; Gray L; Walker AJ; Bortolasci CC; Turner A; Berk M; Walder K; Maes M; Kanchanatawan B; Ashton MM; Berk L; Ng CH; Malhi GS; Singh AB; Dean OM
    Acta Neuropsychiatr; 2022 Aug; 34(4):220-227. PubMed ID: 34937590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive minocycline treatment for major depressive disorder: A proof of concept trial.
    Dean OM; Kanchanatawan B; Ashton M; Mohebbi M; Ng CH; Maes M; Berk L; Sughondhabirom A; Tangwongchai S; Singh AB; McKenzie H; Smith DJ; Malhi GS; Dowling N; Berk M
    Aust N Z J Psychiatry; 2017 Aug; 51(8):829-840. PubMed ID: 28578592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Hellmann-Regen J; Clemens V; Grözinger M; Kornhuber J; Reif A; Prvulovic D; Goya-Maldonado R; Wiltfang J; Gruber O; Schüle C; Padberg F; Ising M; Uhr M; Friede T; Huber C; Manook A; Baghai TC; Rupprecht R; Heuser I
    JAMA Netw Open; 2022 Sep; 5(9):e2230367. PubMed ID: 36103181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial.
    Savitz JB; Teague TK; Misaki M; Macaluso M; Wurfel BE; Meyer M; Drevets D; Yates W; Gleason O; Drevets WC; Preskorn SH
    Transl Psychiatry; 2018 Jan; 8(1):27. PubMed ID: 29362444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression.
    Soczynska JK; Kennedy SH; Alsuwaidan M; Mansur RB; Li M; McAndrews MP; Brietzke E; Woldeyohannes HO; Taylor VH; McIntyre RS
    Bipolar Disord; 2017 May; 19(3):198-213. PubMed ID: 28599348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sex differences in a double-blind randomized clinical trial with minocycline in treatment-resistant depressed patients: CRP and IL-6 as sex-specific predictors of treatment response.
    Lombardo G; Nettis MA; Hastings C; Zajkowska Z; Mariani N; Nikkheslat N; Worrell C; Enache D; McLaughlin A; Kose M; Bogdanova A; Sforzini L; Cleare AJ; Young AH; Dazzan P; Mondelli V; Pariante CM
    Brain Behav Immun Health; 2022 Dec; 26():100561. PubMed ID: 36467125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protocol and rationale-the efficacy of minocycline as an adjunctive treatment for major depressive disorder: a double blind, randomised, placebo controlled trial.
    Dean OM; Maes M; Ashton M; Berk L; Kanchanatawan B; Sughondhabirom A; Tangwongchai S; Ng C; Dowling N; Malhi GS; Berk M
    Clin Psychopharmacol Neurosci; 2014 Dec; 12(3):180-8. PubMed ID: 25598820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of adjunctive celecoxib treatment for patients with major depressive disorder: a meta-analysis.
    Na KS; Lee KJ; Lee JS; Cho YS; Jung HY
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():79-85. PubMed ID: 24056287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring Clinical Subgroups of Participants with Major Depressive Disorder that may Benefit from Adjunctive Minocycline Treatment.
    Anmella G; Meehan A; Ashton M; Mohebbi M; Fico G; Ng CH; Maes M; Berk L; De Prisco M; Singh AB; Malhi GS; Berk M; Dodd S; Hidalgo-Mazzei D; Grande I; Pacchiarotti I; Murru A; Vieta E; Dean OM
    Clin Psychopharmacol Neurosci; 2024 Feb; 22(1):33-44. PubMed ID: 38247410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
    Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
    Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjunctive minocycline for major mental disorders: A systematic review.
    Zheng W; Zhu XM; Zhang QE; Cheng G; Cai DB; He J; Ng CH; Ungvari GS; Peng XJ; Ning YP; Xiang YT
    J Psychopharmacol; 2019 Oct; 33(10):1215-1226. PubMed ID: 31294649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minocycline as adjunctive treatment for treatment-resistant depression: study protocol for a double blind, placebo-controlled, randomized trial (MINDEP2).
    Husain MI; Cullen C; Umer M; Carvalho AF; Kloiber S; Meyer JH; Ortiz A; Knyahnytska Y; Husain MO; Giddens J; Diniz BS; Wang W; Young AH; Mulsant BH; Daskalakis ZJ
    BMC Psychiatry; 2020 Apr; 20(1):173. PubMed ID: 32295565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minocycline and celecoxib as adjunctive treatments for bipolar depression: a multicentre, factorial design randomised controlled trial.
    Husain MI; Chaudhry IB; Khoso AB; Husain MO; Hodsoll J; Ansari MA; Naqvi HA; Minhas FA; Carvalho AF; Meyer JH; Deakin B; Mulsant BH; Husain N; Young AH
    Lancet Psychiatry; 2020 Jun; 7(6):515-527. PubMed ID: 32445690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
    Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
    J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of minocycline for the treatment of bipolar depression: Effects on cortical glutathione and oxidative stress in vivo.
    Murrough JW; Huryk KM; Mao X; Iacoviello B; Collins K; Nierenberg AA; Kang G; Shungu DC; Iosifescu DV
    J Affect Disord; 2018 Apr; 230():56-64. PubMed ID: 29407539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials.
    Rajagopalan K; Bacci ED; Ng-Mak D; Wyrwich K; Pikalov A; Loebel A
    BMC Psychiatry; 2016 May; 16():157. PubMed ID: 27215976
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.